Lista de obras -

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

artículo científico publicado en 2008

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

artículo científico publicado en 2006

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

artículo científico publicado en 2008

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2002

AT-32A PHASE I DOSE-ESCALATION STUDY OF GEMCITABINE PLUS STANDARD RADIATION THERAPY FOR MALIGNANT HIGH GRADE GLIOMAS.

artículo científico publicado en 2014

Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.

artículo científico publicado en 2008

BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases

artículo científico publicado en 2020

Bevacizumab for glioblastoma: what can we learn from patterns of progression?

artículo científico publicado en 2014

Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors

artículo científico publicado en 2017

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2020

Central nervous system cancers

artículo científico publicado en 2008

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines

artículo científico publicado en 2014

Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas

artículo científico publicado en 2022

Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis

artículo científico publicado en 2016

Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas

artículo científico publicado en 2010

Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma

artículo científico publicado en 2011

Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy

artículo científico publicado en 2005

Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy

artículo científico publicado en 2002

Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline

artículo científico publicado en 2011

Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning

artículo científico publicado en 2020

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction.

artículo científico publicado en 2009

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma

artículo científico publicado en 2005

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival

artículo científico publicado en 2008

Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study

artículo científico publicado en 2015

Impact of perfusion map analysis on early survival prediction accuracy in glioma patients

artículo científico publicado en 2013

Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas

artículo científico publicado en 2010

Leptomeningeal metastases: a RANO proposal for response criteria.

artículo científico publicado en 2016

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials

artículo científico publicado en 2014

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

artículo científico publicado en 2019

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

artículo científico publicado en 2017

NCCN task force report: management of neuropathy in cancer

artículo científico publicado en 2009

NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events

artículo científico publicado en 2019

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma

artículo científico publicado en 2010

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

artículo científico publicado en 2004

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

artículo científico publicado en 2004

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study

artículo científico publicado en 2007

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2005

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

artículo científico publicado en 2006

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

artículo científico publicado en 2004

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial

artículo científico publicado en 2004

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

artículo científico publicado en 2006

Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study

artículo científico publicado en 2007

Physiologic and metabolic magnetic resonance imaging in gliomas

artículo científico publicado en 2006

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

artículo científico publicado en 2008

Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment

artículo científico publicado en 2011

Quantitative characterization of hemodynamic properties and vasculature dysfunction of high-grade gliomas.

artículo científico publicado en 2007

Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected].

artículo científico publicado en 2005

The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas.

artículo científico publicado en 2006

The parametric response map is an imaging biomarker for early cancer treatment outcome

artículo científico publicado en 2009

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

artículo científico publicado en 2016

Lista de obras de

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.

AT-32A PHASE I DOSE-ESCALATION STUDY OF GEMCITABINE PLUS STANDARD RADIATION THERAPY FOR MALIGNANT HIGH GRADE GLIOMAS.

Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.

BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases

Bevacizumab for glioblastoma: what can we learn from patterns of progression?

Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Central nervous system cancers

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines

Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas

Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis

Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas

Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma

Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy

Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy

Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline

Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival

Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study

Impact of perfusion map analysis on early survival prediction accuracy in glioma patients

Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas

Leptomeningeal metastases: a RANO proposal for response criteria.

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

NCCN task force report: management of neuropathy in cancer

NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study

Physiologic and metabolic magnetic resonance imaging in gliomas

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment

Quantitative characterization of hemodynamic properties and vasculature dysfunction of high-grade gliomas.

Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected].

The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas.

The parametric response map is an imaging biomarker for early cancer treatment outcome

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial